Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 9/2007

01-09-2007 | Breast Oncology

Blue Dye Injection in the Arm in Order to Conserve the Lymphatic Drainage of the Arm in Breast Cancer Patients Requiring an Axillary Dissection

Authors: Claude Nos, MD, Benedicte Lesieur, MD, Krishna B. Clough, MD, Fabrice Lecuru, PhD

Published in: Annals of Surgical Oncology | Issue 9/2007

Login to get access

Abstract

Background

Despite the widespread use of the sentinel lymph node biopsy technique, many patients with invasive breast cancer still undergo an axillary lymph node dissection and are at risk of arm lymphedema. With the new awareness of lymphatic spread in the axillary nodes, it should be possible to define a new surgical approach between sentinel lymph node biopsy and complete axillary dissection, a procedure preserving specifically lymph nodes in relation to the arm.

Methods

Twenty-one patients with an operable breast cancer requiring an axillary dissection underwent surgery with an attempt to separate nodes related to the breast from specific nodes related to the arm. After an injection of blue dye in the arm, the surgeon performed the axillary dissection trying to identify blue nodes and ducts in order to preserve lymphatic arm drainage (LAD). If the blue nodes were located in the normal axillary dissection, they were removed separately.

Results

In 15 of 21 patients (71%), blue nodes in relation with LAD were identified. In 10 (47%) patients, it was possible to dissect the LAD with the preservation lymphatic ducts. In 10 patients, the LAD nodes were removed: none of them contained metastases, despite the fact that the non-LAD axillary nodes contained metastases in 7 of 10 cases.

Conclusions

Identifying the LAD with blue dye injection in the arm is possible. A subsequent study can now begin to determine if this procedure is safe for patients and able to prevent lymphedema of the arm.
Literature
1.
Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2(6):335–9; discussion 340PubMedCrossRef
2.
Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220(3):391–8; discussion 398–401PubMedCrossRef
3.
Cox CE, Pendas S, Cox JM, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 1998; 227(5):645–51; discussion 651–3PubMedCrossRef
4.
Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349(6):546–53PubMedCrossRef
5.
Blanchard DK, Donohue JH, Reynolds C, Grant CS. Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch Surg 2003; 138(5):482–7; discussion 487–8PubMedCrossRef
6.
Armer J, Fu MR, Wainstock JM, et al. Lymphedema following breast cancer treatment, including sentinel lymph node biopsy. Lymphology 2004; 37(2):73–91PubMed
7.
Silberman AW, McVay C, Cohen JS, et al. Comparative morbidity of axillary lymph node dissection and the sentinel lymph node technique: Implications for patients with breast cancer. Ann Surg 2004; 240(1):1–6PubMedCrossRef
8.
Schwartz GF, Guiliano AE, Veronesi U, Consensus Conference Committee. Proceeding of the consensus conference of the role of sentinel lymph node biopsy in carcinoma or the breast April 19–22, 2001, Philadelphia, PA, USA. Breast J 2002; 8(3):124–38PubMedCrossRef
9.
Petrek JA, Senie RT, Peters M, Rosen PP. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 2001; 92(6):1368–77PubMedCrossRef
10.
Ververs JM, Roumen RM, Vingerhoets AJ, et al. Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer. Eur J Cancer 2001; 37(8):991–9PubMedCrossRef
11.
Utada Y, Kasumi F, Yoshimoto M, et al. The location of positive nodes partly influences the prognostic value of the number of positive nodes in breast cancer patients. Jpn J Clin Oncol 1999; 29(2):63–7PubMedCrossRef
12.
Salama JK, Heimann R, Lin F et al. Does the number of lymph nodes examined in patients with lymph node-negative breast carcinoma have prognostic significance? Cancer 2005; 103(4):664–71PubMedCrossRef
13.
Hama Y, Koyama Y, Urano Y, et al. Simultaneous two-color spectral fluorescence lymphangiography with near infrared quantum dots to map two lymphatic flows from the breast and the upper extremity. Breast Cancer Res Treat 2007; 103(1):23–8PubMedCrossRef
14.
Goffman TE, Laronga C, Wilson L, Elkins D. Lymphedema of the arm and breast in irradiated breast cancer patients: Risks in an era of dramatically changing axillary surgery. Breast J 2004; 10(5):405–11PubMedCrossRef
15.
Lerouge D, Touboul E, Lefranc JP, et al. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: Updated results in a series of 120 patients. Int J Radiat Oncol Biol Phys 2004; 59(4):1062–73PubMedCrossRef
16.
Wilking N, Rutqvist LE, Carstensen J, et al. Prognostic significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes. Stockholm breast cancer study group. Acta Oncol 1992; 31(1):29–35PubMed
17.
Kiricuta CI, Warszawski N, Tausch J, Galimberti V. Incomplete axillary dissection in early breast cancer and the risk of erroneous staging. Oncol Rep 1994; 1:661–6
18.
Palesty JA, Foster JM, Hurd TC, et al. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer. J Surg Oncol 2006; 93(2):129–32PubMedCrossRef
19.
Haid A, Knauer M, Koberle-Wuhrer R, et al. Medium-term follow-up data after sentinel node biopsy alone for breast cancer. Eur J Surg Oncol 2006; 32(10):1180–5PubMedCrossRef
20.
Rosing DK, Dauphine CE, Vargas MP et al. Axillary regional recurrence after sentinel lymph node biopsy for breast cancer. Am Surg 2006; 72(10):939–42PubMed
21.
White RL Jr, Wilke LG. Update on the NSABP and ACOSOG breast cancer sentinel node trials. Am Surg 2004; 70(5):420–4PubMed
22.
Rutgers EJ, Meijnen P, Bonnefoi H, European Organization for Research and Treatment of Cancer Breast Cancer Group. Clinical trials update of the European organization for research and treatment of cancer breast cancer group. Breast Cancer Res 2004; 6(4):165–9PubMedCrossRef
23.
Hidden G. Some recent, or claiming to be recent, data on the superficial lymphatic circulation of the limbs. J Mal Vasc 1990; 15(2):149–51PubMed
24.
O’Mahony S, Rose SL, Chilvers AJ, et al. Finding an optimal method for imaging lymphatic vessels of the upper limb. Eur J Nucl Med Mol Imaging 2004; 31(4):555–63PubMedCrossRef
25.
Goffman TE, Laronga C, Wilson L, et al. Lymphedema of the arm and breast in irradiated breast cancer patients: risks in an era of dramatically changing axillary surgery. Breast J 2004; 10:405–11PubMedCrossRef
26.
Bolla M, Colonna M, Boudinar S. Quels volumes cibles ganglionnaires irradier dans le traitement conservateur du cancer du sein T1–T2 ¾ 3 cm N0–N1 (UICC 1987). Résultats d’une enquête nationale. Bull Cancer/Radiother 1991; 78:81–7 (in French)
Metadata
Title
Blue Dye Injection in the Arm in Order to Conserve the Lymphatic Drainage of the Arm in Breast Cancer Patients Requiring an Axillary Dissection
Authors
Claude Nos, MD
Benedicte Lesieur, MD
Krishna B. Clough, MD
Fabrice Lecuru, PhD
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 9/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9450-4

Other articles of this Issue 9/2007

Annals of Surgical Oncology 9/2007 Go to the issue

Editorials

Appendiceal Carcinoma with Peritoneal Dissemination: Outcomes for the Best of the Best

Endocrine Tumors

Advanced Oxidation Protein Products, Ferrous Oxidation in Xylenol Orange, and Malondialdehyde Levels in Thyroid Cancer

Breast Oncology

Development and Trends of Surgical Modalities for Breast Cancer in China: A Review of 16-Year Data

Multimedia

Transduodenal Excision of Ampullary Polyp with Biliopancreatic Sphincteroplasty

OriginalPaper

Palliative Resection of Colorectal Cancer: Does It Prolong Survival?

Hepatic and Pancreatic Tumors

The Hypoxic Environment in Tumor-Stromal Cells Accelerates Pancreatic Cancer Progression via the Activation of Paracrine Hepatocyte Growth Factor/c-Met Signaling